- Home
- CCSI vs STOK Comparison
CCSI vs STOK Comparison
Compare CCSI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCSI
- STOK
- Stock Information
- Founded
- CCSI 2021
- STOK 2014
- Country
- CCSI United States
- STOK United States
- Employees
- CCSI N/A
- STOK N/A
- Industry
- CCSI Retail: Computer Software & Peripheral Equipment
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CCSI Technology
- STOK Health Care
- Exchange
- CCSI Nasdaq
- STOK Nasdaq
- Market Cap
- CCSI 475.1M
- STOK 517.0M
- IPO Year
- CCSI N/A
- STOK 2019
- Fundamental
- Price
- CCSI $23.20
- STOK $8.93
- Analyst Decision
- CCSI Hold
- STOK Strong Buy
- Analyst Count
- CCSI 5
- STOK 5
- Target Price
- CCSI $27.20
- STOK $27.50
- AVG Volume (30 Days)
- CCSI 146.8K
- STOK 792.0K
- Earning Date
- CCSI 05-07-2025
- STOK 05-13-2025
- Dividend Yield
- CCSI N/A
- STOK N/A
- EPS Growth
- CCSI N/A
- STOK N/A
- EPS
- CCSI 4.32
- STOK 0.88
- Revenue
- CCSI $349,374,000.00
- STOK $190,908,000.00
- Revenue This Year
- CCSI $1.26
- STOK $27.80
- Revenue Next Year
- CCSI $0.88
- STOK $9.53
- P/E Ratio
- CCSI $5.43
- STOK $10.11
- Revenue Growth
- CCSI N/A
- STOK 2333.81
- 52 Week Low
- CCSI $12.67
- STOK $5.35
- 52 Week High
- CCSI $32.10
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- CCSI 65.46
- STOK 51.53
- Support Level
- CCSI $19.24
- STOK $8.30
- Resistance Level
- CCSI $24.03
- STOK $10.12
- Average True Range (ATR)
- CCSI 0.98
- STOK 0.65
- MACD
- CCSI 0.55
- STOK -0.05
- Stochastic Oscillator
- CCSI 83.74
- STOK 29.44
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.